Published in Eur J Immunol on July 01, 2011
The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection. Immunity (2014) 1.40
Oxidative stress in the pathology and treatment of systemic lupus erythematosus. Nat Rev Rheumatol (2013) 1.27
mTOR and lymphocyte metabolism. Curr Opin Immunol (2013) 1.11
Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol (2015) 0.96
mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging. Ann N Y Acad Sci (2015) 0.93
mTOR Links Environmental Signals to T Cell Fate Decisions. Front Immunol (2015) 0.93
Activation of TGF-β-induced non-Smad signaling pathways during Th17 differentiation. Immunol Cell Biol (2015) 0.84
Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development. J Hematol Oncol (2016) 0.78
Combined mTOR inhibition and OX40 agonism enhances CD8(+) T cell memory and protective immunity produced by recombinant adenovirus vaccines. Mol Ther (2011) 0.76
Inappropriate costimulation and aberrant DNA methylation as therapeutic targets in angioimmunoblastic T-cell lymphoma. Biomark Res (2017) 0.75
Identification and characterization of enhancers controlling the inflammatory gene expression program in macrophages. Immunity (2010) 6.48
Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J (2003) 6.46
Transcriptional regulation of macrophage polarization: enabling diversity with identity. Nat Rev Immunol (2011) 6.34
The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell (2007) 6.07
A large fraction of extragenic RNA pol II transcription sites overlap enhancers. PLoS Biol (2010) 6.01
p38-Dependent marking of inflammatory genes for increased NF-kappa B recruitment. Nat Immunol (2001) 4.38
Transcript dynamics of proinflammatory genes revealed by sequence analysis of subcellular RNA fractions. Cell (2012) 4.10
Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med (2003) 3.71
Latent enhancers activated by stimulation in differentiated cells. Cell (2013) 3.44
Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities. Chem Biol (2007) 3.12
A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood (2007) 3.09
Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat Immunol (2002) 3.07
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood (2012) 3.02
Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proc Natl Acad Sci U S A (2009) 3.01
HMG proteins: dynamic players in gene regulation and differentiation. Curr Opin Genet Dev (2005) 2.75
Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol (2004) 2.75
Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J (2009) 2.72
Modulation of NF-kappaB activity by exchange of dimers. Mol Cell (2003) 2.62
Degradation of promoter-bound p65/RelA is essential for the prompt termination of the nuclear factor kappaB response. J Exp Med (2004) 2.50
Noncooperative interactions between transcription factors and clustered DNA binding sites enable graded transcriptional responses to environmental inputs. Mol Cell (2010) 2.43
A hyper-dynamic equilibrium between promoter-bound and nucleoplasmic dimers controls NF-kappaB-dependent gene activity. EMBO J (2006) 2.41
Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma. Cell (2013) 2.28
Substantial histone reduction modulates genomewide nucleosomal occupancy and global transcriptional output. PLoS Biol (2011) 2.26
Platelets mediate cytotoxic T lymphocyte-induced liver damage. Nat Med (2005) 2.19
Interactions of NF-kappaB with chromatin: the art of being at the right place at the right time. Nat Immunol (2005) 2.18
Dynamic changes in histone H3 Lys 9 methylation occurring at tightly regulated inducible inflammatory genes. Genes Dev (2002) 2.10
The histone variant mH2A1.1 interferes with transcription by down-regulating PARP-1 enzymatic activity. Genes Dev (2006) 1.95
Nucleolin is a histone chaperone with FACT-like activity and assists remodeling of nucleosomes. EMBO J (2006) 1.94
Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J Immunol (2006) 1.81
Sustained oscillations of NF-kappaB produce distinct genome scanning and gene expression profiles. PLoS One (2009) 1.81
Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell (2008) 1.80
Mechanism of polymerase II transcription repression by the histone variant macroH2A. Mol Cell Biol (2006) 1.75
Arginine methyltransferase CARM1 is a promoter-specific regulator of NF-kappaB-dependent gene expression. EMBO J (2004) 1.74
In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. Blood (2007) 1.69
Nkx2-5(+)islet1(+) mesenchymal precursors generate distinct spleen stromal cell subsets and participate in restoring stromal network integrity. Immunity (2013) 1.62
Bone marrow as an alternative site for islet transplantation. Blood (2009) 1.61
The histone methyltransferase Wbp7 controls macrophage function through GPI glycolipid anchor synthesis. Immunity (2012) 1.60
The histone H3 lysine 27-specific demethylase Jmjd3 is required for neural commitment. PLoS One (2008) 1.57
IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood (2008) 1.55
Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc Natl Acad Sci U S A (2012) 1.53
Genome-organizing factors Top2 and Hmo1 prevent chromosome fragility at sites of S phase transcription. Cell (2009) 1.48
Platelets prevent IFN-alpha/beta-induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Proc Natl Acad Sci U S A (2008) 1.48
IL-17 protects T cells from apoptosis and contributes to development of ALPS-like phenotypes. Blood (2013) 1.48
A c-Rel subdomain responsible for enhanced DNA-binding affinity and selective gene activation. Genes Dev (2005) 1.45
Defective Th1 cytokine gene transcription in CD4+ and CD8+ T cells from Wiskott-Aldrich syndrome patients. J Immunol (2006) 1.44
Association of chromatin proteins high mobility group box (HMGB) 1 and HMGB2 with mitotic chromosomes. Mol Biol Cell (2003) 1.43
Two modes of transcriptional activation at native promoters by NF-kappaB p65. PLoS Biol (2009) 1.25
Heterochromatin boundaries are hotspots for de novo kinetochore formation. Nat Cell Biol (2011) 1.23
HBV pathogenesis in animal models: recent advances on the role of platelets. J Hepatol (2007) 1.20
Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J Immunol (2012) 1.17
Involvement of Prep1 in the alphabeta T-cell receptor T-lymphocytic potential of hematopoietic precursors. Mol Cell Biol (2005) 1.17
Autonomic denervation of lymphoid organs leads to epigenetic immune atrophy in a mouse model of Krabbe disease. J Neurosci (2007) 1.17
A feed-forward circuit controlling inducible NF-κB target gene activation by promoter histone demethylation. Mol Cell (2010) 1.16
The soluble D2D3(88-274) fragment of the urokinase receptor inhibits monocyte chemotaxis and integrin-dependent cell adhesion. J Cell Sci (2004) 1.14
Reduced functional avidity promotes central and effector memory CD4 T cell responses to tumor-associated antigens. J Immunol (2010) 1.12
Targeted inactivation of the COP9 signalosome impairs multiple stages of T cell development. J Exp Med (2008) 1.08
Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. Transplantation (2008) 1.06
Increased interleukin-10 mRNA stability in melanoma cells is associated with decreased levels of A + U-rich element binding factor AUF1. J Interferon Cytokine Res (2003) 1.05
Antiplatelet drug therapy moderates immune-mediated liver disease and inhibits viral clearance in mice infected with a replication-deficient adenovirus. Clin Vaccine Immunol (2007) 1.04
Cell-type-specific control of enhancer activity by H3K9 trimethylation. Mol Cell (2012) 1.04
Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors. Cancer Res (2006) 1.03
The H3K27 demethylase JMJD3 is required for maintenance of the embryonic respiratory neuronal network, neonatal breathing, and survival. Cell Rep (2012) 1.01
Role of CCL2/MCP-1 in islet transplantation. Cell Transplant (2010) 1.01
The tuberous sclerosis complex: balancing proliferation and survival. Biochem Soc Trans (2011) 1.01
Clonal anergy is maintained independently of T cell proliferation. J Immunol (2002) 1.00
Short-term memory of danger signals and environmental stimuli in immune cells. Nat Immunol (2013) 0.99
Dynamic protein associations define two phases of IL-1beta transcriptional activation. J Immunol (2008) 0.98
AAV6-mediated systemic shRNA delivery reverses disease in a mouse model of facioscapulohumeral muscular dystrophy. Mol Ther (2011) 0.97
Reticulocyte parameters: markers of early response to oral treatment in children with severe iron-deficiency anemia. J Pediatr Hematol Oncol (2012) 0.96
Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes. Cancer Res (2003) 0.95
Chromatin contributions to the regulation of innate immunity. Annu Rev Immunol (2014) 0.95
Cytokine responses in young and old rhesus monkeys: effect of caloric restriction. J Interferon Cytokine Res (2002) 0.94
Prostate cancer stem cells are targets of both innate and adaptive immunity and elicit tumor-specific immune responses. Oncoimmunology (2013) 0.93
Booster vaccinations against cancer are critical in prophylactic but detrimental in therapeutic settings. Cancer Res (2013) 0.93
Cutting edge: An inactive chromatin configuration at the IL-10 locus in human neutrophils. J Immunol (2013) 0.93
Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. Trends Immunol (2008) 0.93
Seasonal environmental changes regulate the expression of the histone variant macroH2A in an eurythermal fish. FEBS Lett (2005) 0.91
Receptor for Advanced Glycation Endproducts is upregulated in temporal lobe epilepsy and contributes to experimental seizures. Neurobiol Dis (2013) 0.90
A signaling loop of REST, TSC2 and β-catenin governs proliferation and function of PC12 neural cells. J Cell Sci (2011) 0.90
Transcriptional control of macrophage diversity and specialization. Eur J Immunol (2011) 0.88
Vaccine-instructed intratumoral IFN-γ enables regression of autochthonous mouse prostate cancer in allogeneic T-cell transplantation. Cancer Res (2013) 0.87
Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo. Eur J Immunol (2008) 0.86
The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use. J Virol Methods (2009) 0.86
Cytosolic sequestration of Prep1 influences early stages of T cell development. PLoS One (2008) 0.86
Phenotype and homing of CD4 tumor-specific T cells is modulated by tumor bulk. J Immunol (2005) 0.85